International journal of heart failure最新文献_第3页

Heart Failure Statistics 2024 Update: A Report From the Korean Society of Heart Failure. 2024 年心力衰竭统计更新：韩国心力衰竭协会报告》。

International journal of heart failure Pub Date : 2024-04-18 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2024.0010

Chan Joo Lee, Hokyou Lee, Minjae Yoon, Kyeong-Hyeon Chun, Min Gyu Kong, Mi-Hyang Jung, In-Cheol Kim, Jae Yeong Cho, Jeehoon Kang, Jin Joo Park, Hyeon Chang Kim, Dong-Ju Choi, Jungkuk Lee, Seok-Min Kang

{"title":"Heart Failure Statistics 2024 Update: A Report From the Korean Society of Heart Failure.","authors":"Chan Joo Lee, Hokyou Lee, Minjae Yoon, Kyeong-Hyeon Chun, Min Gyu Kong, Mi-Hyang Jung, In-Cheol Kim, Jae Yeong Cho, Jeehoon Kang, Jin Joo Park, Hyeon Chang Kim, Dong-Ju Choi, Jungkuk Lee, Seok-Min Kang","doi":"10.36628/ijhf.2024.0010","DOIUrl":"https://doi.org/10.36628/ijhf.2024.0010","url":null,"abstract":"Background and objectives: The number of people with heart failure (HF) is increasing worldwide, and the social burden is increasing as HF has high mortality and morbidity. We aimed to provide updated trends on the epidemiology of HF in Korea to shape future social measures against HF.Methods: We used the National Health Information Database of the National Health Insurance Service to determine the prevalence, incidence, hospitalization rate, mortality rate, comorbidities, in-hospital mortality, and healthcare cost of patients with HF from 2002 to 2020 in Korea.Results: The prevalence of HF in the total Korean population rose from 0.77% in 2002 to 2.58% (1,326,886 people) in 2020. Although the age-standardized incidence of HF decreased over the past 18 years, the age-standardized prevalence increased. In 2020, the hospitalization rate for any cause in patients with HF was 1,166 per 100,000 persons, with a steady increase from 2002. In 2002, the HF mortality was 3.0 per 100,000 persons, which rose to 15.6 per 100,000 persons in 2020. While hospitalization rates and in-hospital mortality for patients with HF increased, the mortality rate for patients with HF did not (5.8% in 2020), and the one-year survival rate from the first diagnosis of HF improved. The total healthcare costs for patients with HF were approximately $2.4 billion in 2020, a 16-fold increase over the $0.15 billion in 2002.Conclusions: The study's results underscore the growing socioeconomic burden of HF in Korea, driven by an aging population and increasing HF prevalence.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 2","pages":"56-69"},"PeriodicalIF":0.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Role of Vitamin D Deficiency Correction in Heart Failure Management: Insights and Prospects. 探索维生素 D 缺乏症纠正在心力衰竭治疗中的作用：洞察与展望

International journal of heart failure Pub Date : 2024-04-17 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2024.0019

Hyung Yoon Kim

引用次数: 0

The Dual Burden of Frailty and Heart Failure. 衰弱和心力衰竭的双重负担。

International journal of heart failure Pub Date : 2024-04-15 eCollection Date: 2024-07-01 DOI: 10.36628/ijhf.2023.0057

Cristiana Vitale, Ilaria Spoletini, Giuseppe M C Rosano

引用次数: 0

The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper. 第三次全国性韩国心衰 III 登记（KorHF III）：研究设计文件。

International journal of heart failure Pub Date : 2024-04-01 DOI: 10.36628/ijhf.2024.0001

Minjae Yoon, Eung Ju Kim, Seong Woo Han, Seong-Mi Park, In-Cheol Kim, Myeong-Chan Cho, Hyo-Suk Ahn, Mi-Seung Shin, Seok Jae Hwang, Jin-Ok Jeong, Dong Heon Yang, Jae-Joong Kim, Jin Oh Choi, Hyun-Jai Cho, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi

{"title":"The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper.","authors":"Minjae Yoon, Eung Ju Kim, Seong Woo Han, Seong-Mi Park, In-Cheol Kim, Myeong-Chan Cho, Hyo-Suk Ahn, Mi-Seung Shin, Seok Jae Hwang, Jin-Ok Jeong, Dong Heon Yang, Jae-Joong Kim, Jin Oh Choi, Hyun-Jai Cho, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi","doi":"10.36628/ijhf.2024.0001","DOIUrl":"https://doi.org/10.36628/ijhf.2024.0001","url":null,"abstract":"With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea. This prospective observational multicenter cohort study (KorHF III) is organized by the Korean Society of Heart Failure. We aim to prospectively enroll 7,000 or more patients hospitalized for AHF at 47 tertiary hospitals in Korea starting from March 2018. Eligible patients exhibit signs and symptoms of HF and demonstrate either lung congestion or objective evidence of structural or functional cardiac abnormalities in echocardiography, or isolated right-sided HF. Patients will be followed up for up to 5 years after enrollment in the registry to evaluate long-term clinical outcomes. KorHF III represents the nationwide AHF registry that will elucidate the clinical characteristics, management strategies, and outcomes of contemporary AHF patients in Korea.Trial registration: ClinicalTrials.gov Identifier: NCT04329234.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 2","pages":"70-75"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF. 精准心脏病学：针对 HFmrEF 和 HFpEF 的表型靶向疗法。

International journal of heart failure Pub Date : 2024-03-25 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2023.0058

Giuseppe M C Rosano, Cristiana Vitale, Ilaria Spoletini

引用次数: 0

Is It Time to Expand the Indication of DOAC to Patients With Cardiac Amyloidosis and Atrial Fibrillation? 是时候将 DOAC 的适应症扩展至心脏淀粉样变性和心房颤动患者了吗？

International journal of heart failure Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2024.0002

So-Ryoung Lee, Jung-Min Choi

引用次数: 0

What Is the Right Direction for the IJHF and Editorial Board? IJHF 和编辑委员会的正确方向是什么？

International journal of heart failure Pub Date : 2024-01-18 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2024.0005

Seong-Mi Park

引用次数: 0

The Relationship Between C-reactive Protein and Takotsubo Syndrome: An Old Riddle. C 反应蛋白与塔克次氏综合征的关系：一个古老的谜团

International journal of heart failure Pub Date : 2024-01-03 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2023.0063

Sunki Lee

引用次数: 0

Application and Potential of Artificial Intelligence in Heart Failure: Past, Present, and Future. 人工智能在心力衰竭中的应用和潜力：过去、现在和未来。

International journal of heart failure Pub Date : 2023-11-30 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2023.0050

Minjae Yoon, Jin Joo Park, Taeho Hur, Cam-Hao Hua, Musarrat Hussain, Sungyoung Lee, Dong-Ju Choi

{"title":"Application and Potential of Artificial Intelligence in Heart Failure: Past, Present, and Future.","authors":"Minjae Yoon, Jin Joo Park, Taeho Hur, Cam-Hao Hua, Musarrat Hussain, Sungyoung Lee, Dong-Ju Choi","doi":"10.36628/ijhf.2023.0050","DOIUrl":"10.36628/ijhf.2023.0050","url":null,"abstract":"The prevalence of heart failure (HF) is increasing, necessitating accurate diagnosis and tailored treatment. The accumulation of clinical information from patients with HF generates big data, which poses challenges for traditional analytical methods. To address this, big data approaches and artificial intelligence (AI) have been developed that can effectively predict future observations and outcomes, enabling precise diagnoses and personalized treatments of patients with HF. Machine learning (ML) is a subfield of AI that allows computers to analyze data, find patterns, and make predictions without explicit instructions. ML can be supervised, unsupervised, or semi-supervised. Deep learning is a branch of ML that uses artificial neural networks with multiple layers to find complex patterns. These AI technologies have shown significant potential in various aspects of HF research, including diagnosis, outcome prediction, classification of HF phenotypes, and optimization of treatment strategies. In addition, integrating multiple data sources, such as electrocardiography, electronic health records, and imaging data, can enhance the diagnostic accuracy of AI algorithms. Currently, wearable devices and remote monitoring aided by AI enable the earlier detection of HF and improved patient care. This review focuses on the rationale behind utilizing AI in HF and explores its various applications.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 1","pages":"11-19"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing Heart Failure Management: A Review of the Clinical Pharmacist Integration to the Multidisciplinary Health Care Team. 优化心力衰竭管理：临床药剂师融入多学科医疗团队的回顾。

International journal of heart failure Pub Date : 2023-11-15 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2023.0022

Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Alonso Quirós-Romero, José Miguel Chaverri-Fernández, Bruno Serrano-Arias, José Pablo Díaz-Madriz, Jonathan García-Montero, Mario Osvaldo Speranza-Sanchez

{"title":"Optimizing Heart Failure Management: A Review of the Clinical Pharmacist Integration to the Multidisciplinary Health Care Team.","authors":"Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Alonso Quirós-Romero, José Miguel Chaverri-Fernández, Bruno Serrano-Arias, José Pablo Díaz-Madriz, Jonathan García-Montero, Mario Osvaldo Speranza-Sanchez","doi":"10.36628/ijhf.2023.0022","DOIUrl":"10.36628/ijhf.2023.0022","url":null,"abstract":"Heart failure (HF) stands as a prevalent chronic ailment, imposing a substantial burden on global healthcare systems due to recurrent hospitalizations, intricate management, persistent symptoms, and polypharmacy challenges. The augmentation of patient safety and treatment efficacy across various care stages, facilitated by a multidisciplinary HF team inclusive of a clinical pharmacist, emerges as paramount. Evidence underscores that the collaborative engagement of a physician and a clinical pharmacist engenders proficient and secure management, forestalling avoidable adversities stemming from drug reactions and prescription inaccuracies. This synergistic approach tailors treatments optimally to individual patients. Post-discharge, the vulnerability of HF patients to re-hospitalization looms large, historically holding sway as the foremost cause of 30-day readmissions. Diverse strategies have been instituted to fortify patient well-being, leading to the formulation of specialized transitional care programs that shepherd patients effectively from hospital to outpatient settings. These initiatives have demonstrably curtailed readmission rates. This review outlines a spectrum of roles assumed by clinical pharmacists within the healthcare cohort, spanning inpatient care, transitional phases, and outpatient services. Moreover, it traverses a compendium of studies spotlighting the affirmative impact instigated by integrating clinical pharmacists into these fields.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":"6 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139674023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0